Dexamethasone treatment study in α-synuclein mice

Validation Score: 0.850 Price: $0.50 Parkinson's disease Thy1.2-α-synuclein transgenic mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting SNCA in Thy1.2-α-synuclein transgenic mice. Primary outcome: microglial response and motor function (wheel-running activity)

Description

A therapeutic intervention study was performed using Thy1.2-α-synuclein mice treated with dexamethasone starting at 5 months of age for 1 month duration. The study assessed the effects of anti-inflammatory treatment on microglial response in the brain and motor function using wheel-running activity tests. Results showed that dexamethasone treatment significantly decreased the microglial response in the brain and promoted functional recovery in motor performance. This experiment demonstrated that inhibiting inflammation can provide beneficial effects on motor phenotypes in an animal model of α-synucleinopathy, supporting the therapeutic potential of anti-inflammatory approaches in Parkinson's disease.

TARGET GENE
MODEL SYSTEM
Thy1.2-α-synuclein transgenic mice
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
neuroinflammation, microglial activation
SOURCE
extracted_from_pmid_25522431
PRIMARY OUTCOME
microglial response and motor function (wheel-running activity)

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.850 composite

📖 Wiki Pages

snca-proteinproteinSNCA→Alpha-synuclein→Parkinson's Disease Causal ChpathwaySNCA→Alpha-synuclein→Aggregation→Lewy Bodies→SynucpathwaySNCA — Alpha-SynucleingeneSNCA — Alpha-Synuclein Gene Entity PagegeneSNCA Gene Variants and MutationsdiseaseSNCA A53TdiseaseSNCA-Overexpressing Dopaminergic NeuronscellSNCA-A53T Alpha-Synuclein NeuronscellParkinproteinMicrogliaentityProdromal Parkinson's DiseasediseaseParkinson's Disease SubtypesdiseaseParkinson's Disease Genetic VariantsdiseaseGut-First vs Brain-First Parkinson's Disease Trajedisease

Protocol

Dexamethasone treatment for 1 month starting at 5 months of age, followed by assessment of brain microglia and wheel-running activity

Expected Outcomes

Reduced microglial response and improved motor function

Success Criteria

Significant decrease in microglial response and functional recovery in motor tests

Related Hypotheses (1)

Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization0.382

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.